Application of myeloid growth factors in the treatment of acute myeloid leukemia

Leukemia

Volumn 11, Issue 3, 1997, Pages 315-327

  Terpstra, W ^a   Lowenberg B ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AML; Cytarabine; Differentiation; G CSF; GM SCF

Indexed keywords

ANTILEUKEMIC AGENT; HEMOPOIETIC GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CYTOTOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030892027     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400561     Document Type: Review

References (10)

1. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F III, Hoag-Iand HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb A), McIntyre OR, for the Cancer and Leukemia Group B. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987; 69: 1441-1449.
2. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosick H, Levi R, Hoagland C, Henry P, Gottlieb A, Cornell C, Behrenberg J, Hutchison JL, Raich P, Nissen N, Allison RR, Frelick F, James GW, Falkson F, Silver RT, Haurani F, Green M, Anderson E, Leone L, Holland JF. Cytosine-arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB Study. Blood 1982; 60: 454-462.
3. Cassileth PA, Lynch E, Haines JD, Oken MM, Mazza JJ, Bennett JM, McGlave JB, Edelstein M, Harrington DP, O'Connel MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
4. Buchner TH, Urnbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, Aul HC, Vaupel HJ, Kuse R, Zeile G, Nowrousian MR, Könog HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassman W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels K, Köppen HM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Koeppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AMD: two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589.
5. Bermann E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Koloitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwae S, Young C, Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
6. Wiernik PH, Banks PLC, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Stood 1992; 79: 313-319.
7. Vogler WR, Velez-Garcia E, Weiner RS, Flaum RA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. I Clin Oncol 1992; 10: 1103-1111.
8. Rees JKH, Gray R. Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia. MRC ninth AML trial. Semin Oncol 1987; 13: 32-36.
9. Yates J, Glidewell O, Wiernik P, Cooper MR, Steiberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine arabinoside with daunomycin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454-463.
10. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.